Antineoplastic Agents: Cytotoxic Agents: Antimetabolites
ICYTO1 “Cytosar-U injection” 500 mg/vial
適應症：急性顆粒白血病及其他急性白血病。
Usual dose:
Leukemia, acute myelogenous: 100 mg/m2/day continuous IV infusion for 7 days or 100 mg/m2 IV q12h for 7 days.
Leukemia, acute myelogenous: high dose induction therapy, 3 g/m2 IV infused over 1-3 h q12h for 2-6 days.
Leukemia, meningeal: 5-75 mg/m2 intrathecally, most Common dose is 30 mg/m2 Intrathecally q4day till normalization of cerebrospinal fluid, followed by 1 additional treatment.
Dose adjustment:
Hematologic: consider holding or discontinue therapy if the platelet count <100,000/mm3 or granulocyte count <1,000/mm3; an increased risk of neurotoxicity is associated with CrCl < 60 ml/min.
Adverse effect:
Common: anorexia, nausea, vomiting, diarrhea, fever, hepatic dysfunction, hyperuricemia, megaloblastosis, reduced reticulocytes, oral and anal inflammation or ulceration, rash, thrombophlebitis.
Serious: anemia, bleeding, anaphylaxis, neuropathy, renal dysfunction, infection, sepsis.